Filter By Service Area
Filter By Title
Filter By Office

Resources

AI Is a Tool, Not a Pharmacist: Louisiana Signals Emerging Oversight

Artificial intelligence (AI) is quickly becoming part of everyday pharmacy operations, and the Louisiana Board of Pharmacy has made clear that it is paying attention. At a recent meeting, the Board discussed the growing use of AI in pharmacy practice and reviewed draft language outlining its current policy position. While that language has not yet been subject to the formal rulemaking process under Louisiana’s Administrative Procedure Act, it offers meaningful insight into how Louisiana’s pharmacy regulators are thinking about AI and what pharmacies should expect going forward.

The draft language states:

“The Board recognizes the use of Artificial Intelligence (AI) as a tool to assist pharmacists in automating routine tasks, enhancing efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and shall not replace the pharmacist’s professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.”

Even in draft form, this language and surrounding discussion is significant. It confirms that the Board is not taking an anti-technology stance. AI is recognized as a legitimate tool that can improve efficiency and potentially enhance patient safety. At the same time, the Board is drawing a clear boundary: AI may assist the pharmacist, but it cannot replace the pharmacist’s independent professional judgment or ultimate responsibility.

During discussion, Board members emphasized that AI should be viewed similarly to other decision-support technologies already embedded in pharmacy systems, such as drug interaction databases and Drug Utilization Review (DUR) platforms. Those tools inform the pharmacist but do not make the final decision. The pharmacist remains accountable for what leaves the pharmacy, regardless of how sophisticated the technology may be.

For Louisiana pharmacies, the practical takeaway is straightforward. Using AI does not eliminate existing legal and regulatory obligations. If an AI tool produces a flawed recommendation, fails to flag an issue, generates inaccurate documentation, or contributes to an incorrect dispensing outcome, the pharmacist and the permit holder remain responsible. AI can inform workflow, but it cannot become the decision-maker.

The Board’s discussion also reflects awareness that AI may enter pharmacy practice in different ways, whether embedded within pharmacy management systems or through external subscription-based vendors offering compliance, workflow, or documentation tools. Those external platforms may raise additional questions involving supervision, patient information, documentation integrity, and scope-of-practice boundaries. Even without immediate new restrictions, pharmacies implementing AI should consider how those systems would be evaluated in the context of an audit, investigation, or disciplinary proceeding.

Importantly, this is highly unlikely to be the end of the conversation. Although the Board has not adopted sweeping AI-specific regulation at this stage, the development of written draft language and public discussion strongly suggest that further rulemaking activity, policy guidance, or formal clarification may follow in the coming months. The Board appears to be staking out an initial framework while preserving flexibility as AI technology and pharmacy use cases continue to evolve.

For pharmacists and pharmacy operators, this is an opportune time to assess how AI is being used in dispensing, clinical review, technician workflow, compliance functions, and documentation processes. Regulators have made clear that innovation is permissible, but professional accountability remains squarely with the licensee.

As this language remains in draft form and is still subject to review and discussion by the Board, it is not yet binding. That said, it offers an important early signal of regulatory direction. We will continue to monitor this process closely and keep you informed as any formal guidance, policy statements, or official rulemaking develops. For pharmacies using or considering using AI tools, staying ahead of the regulatory curve will be critical as Louisiana’s approach continues to take shape.

Sarah Perkins is an attorney in the Baton Rouge office of Breazeale, Sachse & Wilson, L.L.P., where she practices primarily in healthcare law, with additional experience in administrative matters. If you would like more information about this topic, Sarah can be reached through the firm.

AI Is a Tool, Not a Pharmacist: Louisiana Signals Emerging Oversight

Artificial intelligence (AI) is quickly becoming part of everyday pharmacy operations, and the Louisiana Board of Pharmacy has made clear that it is paying attention. At a recent meeting, the Board discussed the growing use of AI in pharmacy practice and reviewed draft language outlining its current policy position. While that language has not yet been subject to the formal rulemaking process under Louisiana’s Administrative Procedure Act, it offers meaningful insight into how Louisiana’s pharmacy regulators are thinking about AI and what pharmacies should expect going forward.

The draft language states:

“The Board recognizes the use of Artificial Intelligence (AI) as a tool to assist pharmacists in automating routine tasks, enhancing efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and shall not replace the pharmacist’s professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.”

Even in draft form, this language and surrounding discussion is significant. It confirms that the Board is not taking an anti-technology stance. AI is recognized as a legitimate tool that can improve efficiency and potentially enhance patient safety. At the same time, the Board is drawing a clear boundary: AI may assist the pharmacist, but it cannot replace the pharmacist’s independent professional judgment or ultimate responsibility.

During discussion, Board members emphasized that AI should be viewed similarly to other decision-support technologies already embedded in pharmacy systems, such as drug interaction databases and Drug Utilization Review (DUR) platforms. Those tools inform the pharmacist but do not make the final decision. The pharmacist remains accountable for what leaves the pharmacy, regardless of how sophisticated the technology may be.

For Louisiana pharmacies, the practical takeaway is straightforward. Using AI does not eliminate existing legal and regulatory obligations. If an AI tool produces a flawed recommendation, fails to flag an issue, generates inaccurate documentation, or contributes to an incorrect dispensing outcome, the pharmacist and the permit holder remain responsible. AI can inform workflow, but it cannot become the decision-maker.

The Board’s discussion also reflects awareness that AI may enter pharmacy practice in different ways, whether embedded within pharmacy management systems or through external subscription-based vendors offering compliance, workflow, or documentation tools. Those external platforms may raise additional questions involving supervision, patient information, documentation integrity, and scope-of-practice boundaries. Even without immediate new restrictions, pharmacies implementing AI should consider how those systems would be evaluated in the context of an audit, investigation, or disciplinary proceeding.

Importantly, this is highly unlikely to be the end of the conversation. Although the Board has not adopted sweeping AI-specific regulation at this stage, the development of written draft language and public discussion strongly suggest that further rulemaking activity, policy guidance, or formal clarification may follow in the coming months. The Board appears to be staking out an initial framework while preserving flexibility as AI technology and pharmacy use cases continue to evolve.

For pharmacists and pharmacy operators, this is an opportune time to assess how AI is being used in dispensing, clinical review, technician workflow, compliance functions, and documentation processes. Regulators have made clear that innovation is permissible, but professional accountability remains squarely with the licensee.

As this language remains in draft form and is still subject to review and discussion by the Board, it is not yet binding. That said, it offers an important early signal of regulatory direction. We will continue to monitor this process closely and keep you informed as any formal guidance, policy statements, or official rulemaking develops. For pharmacies using or considering using AI tools, staying ahead of the regulatory curve will be critical as Louisiana’s approach continues to take shape.

Sarah Perkins is an attorney in the Baton Rouge office of Breazeale, Sachse & Wilson, L.L.P., where she practices primarily in healthcare law, with additional experience in administrative matters. If you would like more information about this topic, Sarah can be reached through the firm.

AI Is a Tool, Not a Pharmacist: Louisiana Signals Emerging Oversight

Artificial intelligence (AI) is quickly becoming part of everyday pharmacy operations, and the Louisiana Board of Pharmacy has made clear that it is paying attention. At a recent meeting, the Board discussed the growing use of AI in pharmacy practice and reviewed draft language outlining its current policy position. While that language has not yet been subject to the formal rulemaking process under Louisiana’s Administrative Procedure Act, it offers meaningful insight into how Louisiana’s pharmacy regulators are thinking about AI and what pharmacies should expect going forward.

The draft language states:

“The Board recognizes the use of Artificial Intelligence (AI) as a tool to assist pharmacists in automating routine tasks, enhancing efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and shall not replace the pharmacist’s professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.”

Even in draft form, this language and surrounding discussion is significant. It confirms that the Board is not taking an anti-technology stance. AI is recognized as a legitimate tool that can improve efficiency and potentially enhance patient safety. At the same time, the Board is drawing a clear boundary: AI may assist the pharmacist, but it cannot replace the pharmacist’s independent professional judgment or ultimate responsibility.

During discussion, Board members emphasized that AI should be viewed similarly to other decision-support technologies already embedded in pharmacy systems, such as drug interaction databases and Drug Utilization Review (DUR) platforms. Those tools inform the pharmacist but do not make the final decision. The pharmacist remains accountable for what leaves the pharmacy, regardless of how sophisticated the technology may be.

For Louisiana pharmacies, the practical takeaway is straightforward. Using AI does not eliminate existing legal and regulatory obligations. If an AI tool produces a flawed recommendation, fails to flag an issue, generates inaccurate documentation, or contributes to an incorrect dispensing outcome, the pharmacist and the permit holder remain responsible. AI can inform workflow, but it cannot become the decision-maker.

The Board’s discussion also reflects awareness that AI may enter pharmacy practice in different ways, whether embedded within pharmacy management systems or through external subscription-based vendors offering compliance, workflow, or documentation tools. Those external platforms may raise additional questions involving supervision, patient information, documentation integrity, and scope-of-practice boundaries. Even without immediate new restrictions, pharmacies implementing AI should consider how those systems would be evaluated in the context of an audit, investigation, or disciplinary proceeding.

Importantly, this is highly unlikely to be the end of the conversation. Although the Board has not adopted sweeping AI-specific regulation at this stage, the development of written draft language and public discussion strongly suggest that further rulemaking activity, policy guidance, or formal clarification may follow in the coming months. The Board appears to be staking out an initial framework while preserving flexibility as AI technology and pharmacy use cases continue to evolve.

For pharmacists and pharmacy operators, this is an opportune time to assess how AI is being used in dispensing, clinical review, technician workflow, compliance functions, and documentation processes. Regulators have made clear that innovation is permissible, but professional accountability remains squarely with the licensee.

As this language remains in draft form and is still subject to review and discussion by the Board, it is not yet binding. That said, it offers an important early signal of regulatory direction. We will continue to monitor this process closely and keep you informed as any formal guidance, policy statements, or official rulemaking develops. For pharmacies using or considering using AI tools, staying ahead of the regulatory curve will be critical as Louisiana’s approach continues to take shape.

Sarah Perkins is an attorney in the Baton Rouge office of Breazeale, Sachse & Wilson, L.L.P., where she practices primarily in healthcare law, with additional experience in administrative matters. If you would like more information about this topic, Sarah can be reached through the firm.

AI Is a Tool, Not a Pharmacist: Louisiana Signals Emerging Oversight

Artificial intelligence (AI) is quickly becoming part of everyday pharmacy operations, and the Louisiana Board of Pharmacy has made clear that it is paying attention. At a recent meeting, the Board discussed the growing use of AI in pharmacy practice and reviewed draft language outlining its current policy position. While that language has not yet been subject to the formal rulemaking process under Louisiana’s Administrative Procedure Act, it offers meaningful insight into how Louisiana’s pharmacy regulators are thinking about AI and what pharmacies should expect going forward.

The draft language states:

“The Board recognizes the use of Artificial Intelligence (AI) as a tool to assist pharmacists in automating routine tasks, enhancing efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and shall not replace the pharmacist’s professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.”

Even in draft form, this language and surrounding discussion is significant. It confirms that the Board is not taking an anti-technology stance. AI is recognized as a legitimate tool that can improve efficiency and potentially enhance patient safety. At the same time, the Board is drawing a clear boundary: AI may assist the pharmacist, but it cannot replace the pharmacist’s independent professional judgment or ultimate responsibility.

During discussion, Board members emphasized that AI should be viewed similarly to other decision-support technologies already embedded in pharmacy systems, such as drug interaction databases and Drug Utilization Review (DUR) platforms. Those tools inform the pharmacist but do not make the final decision. The pharmacist remains accountable for what leaves the pharmacy, regardless of how sophisticated the technology may be.

For Louisiana pharmacies, the practical takeaway is straightforward. Using AI does not eliminate existing legal and regulatory obligations. If an AI tool produces a flawed recommendation, fails to flag an issue, generates inaccurate documentation, or contributes to an incorrect dispensing outcome, the pharmacist and the permit holder remain responsible. AI can inform workflow, but it cannot become the decision-maker.

The Board’s discussion also reflects awareness that AI may enter pharmacy practice in different ways, whether embedded within pharmacy management systems or through external subscription-based vendors offering compliance, workflow, or documentation tools. Those external platforms may raise additional questions involving supervision, patient information, documentation integrity, and scope-of-practice boundaries. Even without immediate new restrictions, pharmacies implementing AI should consider how those systems would be evaluated in the context of an audit, investigation, or disciplinary proceeding.

Importantly, this is highly unlikely to be the end of the conversation. Although the Board has not adopted sweeping AI-specific regulation at this stage, the development of written draft language and public discussion strongly suggest that further rulemaking activity, policy guidance, or formal clarification may follow in the coming months. The Board appears to be staking out an initial framework while preserving flexibility as AI technology and pharmacy use cases continue to evolve.

For pharmacists and pharmacy operators, this is an opportune time to assess how AI is being used in dispensing, clinical review, technician workflow, compliance functions, and documentation processes. Regulators have made clear that innovation is permissible, but professional accountability remains squarely with the licensee.

As this language remains in draft form and is still subject to review and discussion by the Board, it is not yet binding. That said, it offers an important early signal of regulatory direction. We will continue to monitor this process closely and keep you informed as any formal guidance, policy statements, or official rulemaking develops. For pharmacies using or considering using AI tools, staying ahead of the regulatory curve will be critical as Louisiana’s approach continues to take shape.

Sarah Perkins is an attorney in the Baton Rouge office of Breazeale, Sachse & Wilson, L.L.P., where she practices primarily in healthcare law, with additional experience in administrative matters. If you would like more information about this topic, Sarah can be reached through the firm.

AI Is a Tool, Not a Pharmacist: Louisiana Signals Emerging Oversight

Artificial intelligence (AI) is quickly becoming part of everyday pharmacy operations, and the Louisiana Board of Pharmacy has made clear that it is paying attention. At a recent meeting, the Board discussed the growing use of AI in pharmacy practice and reviewed draft language outlining its current policy position. While that language has not yet been subject to the formal rulemaking process under Louisiana’s Administrative Procedure Act, it offers meaningful insight into how Louisiana’s pharmacy regulators are thinking about AI and what pharmacies should expect going forward.

The draft language states:

“The Board recognizes the use of Artificial Intelligence (AI) as a tool to assist pharmacists in automating routine tasks, enhancing efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and shall not replace the pharmacist’s professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.”

Even in draft form, this language and surrounding discussion is significant. It confirms that the Board is not taking an anti-technology stance. AI is recognized as a legitimate tool that can improve efficiency and potentially enhance patient safety. At the same time, the Board is drawing a clear boundary: AI may assist the pharmacist, but it cannot replace the pharmacist’s independent professional judgment or ultimate responsibility.

During discussion, Board members emphasized that AI should be viewed similarly to other decision-support technologies already embedded in pharmacy systems, such as drug interaction databases and Drug Utilization Review (DUR) platforms. Those tools inform the pharmacist but do not make the final decision. The pharmacist remains accountable for what leaves the pharmacy, regardless of how sophisticated the technology may be.

For Louisiana pharmacies, the practical takeaway is straightforward. Using AI does not eliminate existing legal and regulatory obligations. If an AI tool produces a flawed recommendation, fails to flag an issue, generates inaccurate documentation, or contributes to an incorrect dispensing outcome, the pharmacist and the permit holder remain responsible. AI can inform workflow, but it cannot become the decision-maker.

The Board’s discussion also reflects awareness that AI may enter pharmacy practice in different ways, whether embedded within pharmacy management systems or through external subscription-based vendors offering compliance, workflow, or documentation tools. Those external platforms may raise additional questions involving supervision, patient information, documentation integrity, and scope-of-practice boundaries. Even without immediate new restrictions, pharmacies implementing AI should consider how those systems would be evaluated in the context of an audit, investigation, or disciplinary proceeding.

Importantly, this is highly unlikely to be the end of the conversation. Although the Board has not adopted sweeping AI-specific regulation at this stage, the development of written draft language and public discussion strongly suggest that further rulemaking activity, policy guidance, or formal clarification may follow in the coming months. The Board appears to be staking out an initial framework while preserving flexibility as AI technology and pharmacy use cases continue to evolve.

For pharmacists and pharmacy operators, this is an opportune time to assess how AI is being used in dispensing, clinical review, technician workflow, compliance functions, and documentation processes. Regulators have made clear that innovation is permissible, but professional accountability remains squarely with the licensee.

As this language remains in draft form and is still subject to review and discussion by the Board, it is not yet binding. That said, it offers an important early signal of regulatory direction. We will continue to monitor this process closely and keep you informed as any formal guidance, policy statements, or official rulemaking develops. For pharmacies using or considering using AI tools, staying ahead of the regulatory curve will be critical as Louisiana’s approach continues to take shape.

Sarah Perkins is an attorney in the Baton Rouge office of Breazeale, Sachse & Wilson, L.L.P., where she practices primarily in healthcare law, with additional experience in administrative matters. If you would like more information about this topic, Sarah can be reached through the firm.

AI Is a Tool, Not a Pharmacist: Louisiana Signals Emerging Oversight

Artificial intelligence (AI) is quickly becoming part of everyday pharmacy operations, and the Louisiana Board of Pharmacy has made clear that it is paying attention. At a recent meeting, the Board discussed the growing use of AI in pharmacy practice and reviewed draft language outlining its current policy position. While that language has not yet been subject to the formal rulemaking process under Louisiana’s Administrative Procedure Act, it offers meaningful insight into how Louisiana’s pharmacy regulators are thinking about AI and what pharmacies should expect going forward.

The draft language states:

“The Board recognizes the use of Artificial Intelligence (AI) as a tool to assist pharmacists in automating routine tasks, enhancing efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and shall not replace the pharmacist’s professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.”

Even in draft form, this language and surrounding discussion is significant. It confirms that the Board is not taking an anti-technology stance. AI is recognized as a legitimate tool that can improve efficiency and potentially enhance patient safety. At the same time, the Board is drawing a clear boundary: AI may assist the pharmacist, but it cannot replace the pharmacist’s independent professional judgment or ultimate responsibility.

During discussion, Board members emphasized that AI should be viewed similarly to other decision-support technologies already embedded in pharmacy systems, such as drug interaction databases and Drug Utilization Review (DUR) platforms. Those tools inform the pharmacist but do not make the final decision. The pharmacist remains accountable for what leaves the pharmacy, regardless of how sophisticated the technology may be.

For Louisiana pharmacies, the practical takeaway is straightforward. Using AI does not eliminate existing legal and regulatory obligations. If an AI tool produces a flawed recommendation, fails to flag an issue, generates inaccurate documentation, or contributes to an incorrect dispensing outcome, the pharmacist and the permit holder remain responsible. AI can inform workflow, but it cannot become the decision-maker.

The Board’s discussion also reflects awareness that AI may enter pharmacy practice in different ways, whether embedded within pharmacy management systems or through external subscription-based vendors offering compliance, workflow, or documentation tools. Those external platforms may raise additional questions involving supervision, patient information, documentation integrity, and scope-of-practice boundaries. Even without immediate new restrictions, pharmacies implementing AI should consider how those systems would be evaluated in the context of an audit, investigation, or disciplinary proceeding.

Importantly, this is highly unlikely to be the end of the conversation. Although the Board has not adopted sweeping AI-specific regulation at this stage, the development of written draft language and public discussion strongly suggest that further rulemaking activity, policy guidance, or formal clarification may follow in the coming months. The Board appears to be staking out an initial framework while preserving flexibility as AI technology and pharmacy use cases continue to evolve.

For pharmacists and pharmacy operators, this is an opportune time to assess how AI is being used in dispensing, clinical review, technician workflow, compliance functions, and documentation processes. Regulators have made clear that innovation is permissible, but professional accountability remains squarely with the licensee.

As this language remains in draft form and is still subject to review and discussion by the Board, it is not yet binding. That said, it offers an important early signal of regulatory direction. We will continue to monitor this process closely and keep you informed as any formal guidance, policy statements, or official rulemaking develops. For pharmacies using or considering using AI tools, staying ahead of the regulatory curve will be critical as Louisiana’s approach continues to take shape.

Sarah Perkins is an attorney in the Baton Rouge office of Breazeale, Sachse & Wilson, L.L.P., where she practices primarily in healthcare law, with additional experience in administrative matters. If you would like more information about this topic, Sarah can be reached through the firm.